SCHEMBL12561702

SCHEMBL12561702

Oc1cccc(-c2nc(-c3ccc(-c4ccccc4)cc3)c(-c3ccccc3)[nH]2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 1.00
MAPK13 O15264 6/20 0.72
MAPK12 P53778 6/20 0.72
MAPK11 Q15759 6/20 0.72
MAPK14 Q16539 6/20 0.72
RAF1 P04049 4/20 0.72
BRAF P15056 2/20 0.72
BRDT Q58F21 1/20 0.72
MAPT P10636 4/20 0.63
TP53 P04637 3/20 0.63
GCGR P47871 2/20 0.63
NOX1 Q9Y5S8 3/20 0.61
MGAM O43451 1/20 0.57
SMPD3 Q9NY59 1/20 0.57
MAPK9 P45984 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068914 0.97 PTPN1 (0.94) PTPN1MAPK13MAPK12MAPK11MAPK14
SCHEMBL6469184 0.90 MAPK14 (0.90) PTPN1MAPK13MAPK12MAPK11MAPK14
SCHEMBL5624801 0.88 MAPK14 (0.81) PTPN1MAPK13MAPK12MAPK11MAPK14
SCHEMBL12561713 0.86 MAPK13 (0.83) PTPN1MAPK13MAPK12MAPK11MAPK14
SCHEMBL31255400 0.86 MAPK13 (0.83) PTPN1MAPK13MAPK12MAPK11MAPK14
SCHEMBL14514175 0.85 PTPN1 (0.73) PTPN1MAPK13MAPK12MAPK11MAPK14
SCHEMBL9619859 0.84 MAPK13 (0.85) PTPN1MAPK13MAPK12MAPK11MAPK14
SCHEMBL15401173 0.84 MAPK13 (0.85) PTPN1MAPK13MAPK12MAPK11MAPK14
SCHEMBL252964 0.84 MAPK13 (0.85) PTPN1MAPK13MAPK12MAPK11MAPK14
Phloroglucinol SCHEMBL28606657 0.84 PTPN1 (0.72) PTPN1MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC. (CA) 2015-12-31 US disclosed
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC. (CA) 2015-12-31 US disclosed
US-8987305-B2 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents APTOSE BIOSCIENCES INC. (CA) 2015-03-24 US disclosed
US-8987305-B2 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents APTOSE BIOSCIENCES INC. (CA) 2015-03-24 US disclosed
US-8969372-B2 Aryl imidazoles and their use as anti-cancer agents Aptose Boisciences Inc. (CA) 2015-03-03 US disclosed
US-8969372-B2 Aryl imidazoles and their use as anti-cancer agents Aptose Boisciences Inc. (CA) 2015-03-03 US disclosed
US-20130177632-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS APTOSE BIOSCIENCES INC. (CA) 2013-07-11 US disclosed
US-20130177632-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS APTOSE BIOSCIENCES INC. (CA) 2013-07-11 US disclosed
US-8394815-B2 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents LORUS THERAPEUTICS INC. (CA) 2013-03-12 US disclosed
US-8394815-B2 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents LORUS THERAPEUTICS INC. (CA) 2013-03-12 US disclosed
US-20110152337-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS LORUS THERAPEUTICS INC. (CA) 2011-06-23 US disclosed
US-7884120-B2 microbiocides such as 2-(2-methyl-1H-indol-3-yl)-3a,11b-dihydro-1H-phenanthro[9,10-d]imidazole; bactericides; fungicides LORUS THERAPEUTICS INC. (CA) 2011-02-08 US disclosed
US-7884120-B2 microbiocides such as 2-(2-methyl-1H-indol-3-yl)-3a,11b-dihydro-1H-phenanthro[9,10-d]imidazole; bactericides; fungicides LORUS THERAPEUTICS INC. (CA) 2011-02-08 US disclosed
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2008-10-23 US disclosed
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2008-10-23 US disclosed
WO-2005047266-A9 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC (CA) 2008-04-17 WO disclosed
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2007-05-31 US disclosed
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2007-05-31 US disclosed
US-20070105929-A1 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents APTOSE BIOSCIENCES INC. (CA) 2007-05-10 US disclosed
US-20070105929-A1 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents APTOSE BIOSCIENCES INC. (CA) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130177632-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS IDO2, ERG28, IL4 PTPN1 1231/4885MAPK13 3668/4885MAPK12 3161/4885
US-20110152337-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS IDO2, ERG28, IL4 PTPN1 1231/4885MAPK13 3668/4885MAPK12 3161/4885
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents AHR, AADAC, CBR3 PTPN1 879/4885MAPK13 4059/4885MAPK12 3204/4885
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS AHR, CBR3, AADAC PTPN1 906/4885MAPK13 4087/4885MAPK12 3446/4885
US-20070105929-A1 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents IDO2, ERG28, IL4 PTPN1 1231/4885MAPK13 3668/4885MAPK12 3161/4885
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents AHR, AADAC, CBR3 PTPN1 879/4885MAPK13 4059/4885MAPK12 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.